Mark Cuban Cost Plus Drug Company revealed Starjemza will be joining the company’s portfolio of medications, representing a key milestone in Cost Plus Drugs growth while also expanding access for patients to specialty medicines.¹

"The addition of Starjemza® reflects the strength of our partnerships and the steady progress of our mission," said Alan Bowe, chief commercial officer of Cost Plus Drugs. "We remain focused on expanding access across all therapeutic categories and proving that transparency and value can exist together in a sustainable way. This is not a single disruption but part of an ongoing shift toward a healthcare system that works for everyone."

Why did Cost Plus Drugs add Starjemza to its portfolio?

Starjemza, a new biosimilar medication used to treat chronic inflammatory conditions, is part of Cost Plus Drugs’ mission to challenge traditional economics for specialty medications and deliver understandable pricing to patients.¹ Specialty medications are typically amongst the most expensive medications in the US, accounting for a signification amount of the national drug spending, and just a small percentage of total prescriptions.¹ By adding a special medication therapy like Starjemza to its portfolio, Cost Plus Drugs will apply its transparent cost-plus pricing model to the medicine in attempts to increase availability and access at a discounted cost compared to market price.¹

What is the cost-plus pricing model?

Mark Cuban’s Cost Plus Drugs employs its cost-plus pricing model, a pricing modality clearly displaying each cost component.¹ Each medication offered through the platform is priced in accordance with the medicines acquisition cost, along with a modest fixed markup and pharmacy fee.¹ As part of the cost plus pricing model, Starjemza is set to be listed at a starting price of $345 per quarter, plus shipping, for the 90 mg/mL pre-filled syringe, with additional configurations, including the 45 mg/mL and 130 mg/mL pre-filled syringes, will also be offered and priced in accordance with the company's transparent cost-plus model.

"Our goal has always been to make sure that no one is priced out of the medication they need," said Mark Cuban, co-founder of Cost Plus Drugs. "Starjemza is another example of how transparency and fair pricing can make a real difference for people who have been paying inflated costs for far too long. We are building a model that prioritizes access, honesty and trust."

Cost Plus Drugs Partnership with Medchat.ai

Along with expanding its special medications portfolio, Cost Plus Drugs is also expanding its customer support, as the company recently announced its partnership with Medchat.ai, enhancing customer support and accelerating patient access to safe and affordable medications.² The collaboration brings Cost Plus Drugs AI customer care agents, delivering fast and personalized support to patients.

"We are thrilled to collaborate with Medchat•ai in our mission to make prescription drugs more accessible and affordable for consumers," said Dr. Alex Oshmyansky, co-founder and CEO of Mark Cuban Cost Plus Drugs. "At Cost Plus Drugs, our commitment to transparent drug pricing has always been at the core of everything we do, and with partners like Medchat•ai, we are now able to bring a level of support to consumers that matches our mission."

Sources

1. Mark Cuban Cost Plus Drug Company Expands Access with Addition of Starjemza® (ustekinumab-hmny) to Give Patients More Power Over Prescription Costs Mark Cuban Cost Plus Drugs November 6, 2025 https://www.prnewswire.com/news-releases/mark-cuban-cost-plus-drug-company-expands-access-with-addition-of-starjemza-ustekinumab-hmny-to-give-patients-more-power-over-prescription-costs-302606318.html
2. Mark Cuban Cost Plus Drugs and Medchat•ai Deploy AI to Scale Affordable Medication Access Medchat.ai October 28, 2025 https://www.prnewswire.com/news-releases/mark-cuban-cost-plus-drugs-and-medchatai-deploy-ai-to-scale-affordable-medication-access-302596860.html